Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Aroda VR, Aberle J, Bardtrum L, et al.
The Lancet 2023. Pub. online 25 June 2023.
Leggi